{"organizations": [], "uuid": "f41c9b1785a72a7b99d12a5e7342e72d70fe0c59", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/7", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/01/31/pr-newswire-qiagen-reports-results-for-fourth-quarter-and-full-year-2017-announces-stat-dx-acquisition-and-new-200-million-share.html", "country": "US", "domain_rank": 767, "title": "QIAGEN Reports for Full-year 2017, Announces STAT-Dx Acquisition and New $200 Million Share Repurchase", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-01T00:10:00.000+02:00", "replies_count": 0, "uuid": "f41c9b1785a72a7b99d12a5e7342e72d70fe0c59"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/01/31/pr-newswire-qiagen-reports-results-for-fourth-quarter-and-full-year-2017-announces-stat-dx-acquisition-and-new-200-million-share.html", "ord_in_thread": 0, "title": "QIAGEN Reports for Full-year 2017, Announces STAT-Dx Acquisition and New $200 Million Share Repurchase", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "VENLO, Netherlands, January 31, 2018 /PRNewswire/ --\nSolid Q4 results as QIAGEN achieves full-year 2017 targets : Q4 2017: Net sales $ 396. 9 million (+8% actual, +5 % CER); adjusted net sales rise 6 % CER excluding portfolio change s vs. 5-6 % CER guidance Q4 2017: EPS - $0. 18 including impact of predominantly non-cash U.S. tax reform charge ; adjusted EPS $0. 43 ($0. 43 CER) vs. ~$0.4 1 -4 2 CER guidance Full-year 2017: Achieved guidance with 7% CER adjusted net sales growth excluding portfolio changes and adjusted diluted EPS of $1.27 CER Full-year 2017 : Adjusted operating income margin improves to 26 % of adjusted sales from 24 % in 2016 New $200 million share repurchase commitment through open-market repurchase Acquisition of STAT-Dx adds QIAstat-Dx, a next - generation PCR-based multiplex syndromic testing solution with expected European launch in second half of 2018 Q IAGEN sets 2018 outlook for further growth in adjusted net sales and adjusted EPS , reaffirms 2020 mid-term targets for improving performance\nQIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the fourth quarter and full-year 2017, delivering on goals for adjusted net sales and adjusted earnings per share while driving the global expansion of its Sample to Insight portfolio of molecular testing solutions covering the continuum from basic research to clinical healthcare.\nFor the full press release click here\n(Link: https://corporate.qiagen.com/newsroom/press-releases/2018/20180131_q4fy2018_results?sc_lang=en )\nContacts\nInvestor Relations:\nJohn Gilardi\nVice President Corporate Communications and Investor Relations\n+49-2103-29 11711 and +1-240-686-2222\nJohn.gilardi@qiagen.com\nDr. Sarah Fakih\nAssociate Director Investor Relations\n+49-2103-29-11457\nSarah.fakih@qiagen.com\nPublic Relations:\nDr. Thomas Theuringer\nSenior Director Public Relations and Digital Communications\n+49-2103-29-11826 and +1-240-686-7425\nThomas.theuringer@qiagen.com\nSOURCE Qiagen N.V.", "external_links": ["https://corporate.qiagen.com/newsroom/press-releases/2018/20180131_q4fy2018_results?sc_lang=en"], "published": "2018-02-01T00:10:00.000+02:00", "crawled": "2018-02-01T02:50:21.033+02:00", "highlightTitle": ""}